

FBN1 Full Gene Sequencing with Deletion/ Duplication (MFBNG) Prior Authorization Ordering Instructions

Mayo Clinic Laboratories is pleased to offer prior authorization services and third party billing on our *FBN1* Full Gene Sequencing with Deletion/Duplications, Varies (MFBNG). To utilize our prior authorization services on this test, you must follow the process as outlined below.

Ordering and Prior Authorization Process

Mayo Clinic Laboratories utilizes an extract and hold process for prior authorization. To order MFBNG with prior authorization services, complete this document as instructed below by insurance type. You must order test code MFBNG and send the completed paperwork in with the sample. The receipt of the paperwork and sample at Mayo Clinic Laboratories will trigger the extract and hold process and generate a request to the MCL Business Office to verify your patient's insurance coverage for the testing and begin any additional prior authorization services.

If the expected patient out-of-pocket expense is \$200 or less after prior authorization services, Mayo Clinic Laboratories will automatically proceed with MFBNG testing. If the expected patient out-of-pocket expense is greater than \$200, Mayo Clinic Laboratories will seek approval from the client contact listed on the Patient Demographics and Third Party Billing Information form **before proceeding** with MFBNG testing. The MCL Business Office offers interest-free payment plans on balances over \$200.

Commercial Insurance

For patients with commercial insurance, complete the following, staple them together and send with the specimen:

- Patient Demographics and Third Party Billing Information form (required)
- Letter of Medical Necessity (required)
- Copy of front and back of insurance card (if available)

Note: The Advanced Beneficiary Notice of Noncoverage (ABN) form is not required for commercial insurance-covered patients.

Medicare

For patients with Medicare, complete the following, staple them together and send with the specimen:

- Patient Demographics and Third Party Billing Information form (required)
- Advanced Beneficiary Notice of Noncoverage (ABN) form (required see separate ABN form: MC2934-336)
- Copy of front and back of secondary insurance card (if applicable)

Attach the ABN form and copy of the secondary insurance card to the Patient Demographics and Third Party Billing Information form and send with the specimen.

Note: The Letter of Medical Necessity and a copy of the Medicare card are not required for Medicare-covered patients.

Medicaid

Mayo Clinic Laboratories may be able to file claims for your Medicaid-covered patients. Before ordering, contact the MCL Business Office at 800-447-6424 to discuss. Have the patient's Medicaid information available when calling.

Note: These instructions are subject to change at any time. Call the MCL Business Office at 800-447-6424 with any questions.



Prior Authorization Patient Demographics and Third Party Billing Information

Client Order Number	\neg				
Dations Domanous discount Income					
Patient Demographics and Insurance Patient Name (Last, First Middle)	Information	ı	Birth Da	te (mm-dd-yyyy)	
Sex Assigned at Birth		Legal/Adminis			
	ose not to disclose	☐ Male ☐ I			
Patient Mailing Address		City	State	ZIP Code	
Primary Insurance Company Name	Insurance Subscrib	er ID No. / Policy No.	Insurance Group	No. (if applicable)	
Primary Insurance Company Mailing Address		City	State	ZIP Code	
Primary Insurance Company Phone	Subscriber Name (i	Subscriber Name (if different than patient) and Relationship to Patient			
Order Information	1				
MCL Test ID	Name of desired M	CL test	'	'	
MFBNG	FBN1 Full Gene Sec	quencing with Deletior	n/Duplications, V	aries	
ICD-10 Codes (use number codes to highest sp	pecificity)		Service/Collecti	on Date (mm-dd-yyyy)	
Referring Provider Name (Last, First)		Referring Provider's National Provider ID (NPI)			
Client Account and Client Contact In	ıformation				
MCL Client Account Number (if known)	Referring Client Facility Name				
Contact Name		Contact Phon	e		
Contact Email		Date Today (m	Date Today (mm-dd-yyyy)		
Attach the Following to This Comple	ted Form				
Letter of Medical Necessity (required except		mplate provided on pa	ge 3		
Advanced Beneficiary Notice of Noncoverage	e (ABN) form (required for I	Medicare patients only)	– see separate fo	orm: MC2934-336	
∘ Templates provided on the following pag	ges				
Copy of front and back of patient's insurance	e card (if available)				

Page 2 of 4 MC7226-50rev1224

Letter of Medical Necessity for FBN1 Full Gene Sequencing with Deletion/Duplication (MFBNG) Testing Patient Name (Last, First Middle) Birth Date (mm-dd-yyyy) Member Number Group ICD-10 Codes To Whom It May Concern: We are requesting preauthorization for the FBN1 Full Gene Sequencing with Deletion/Duplication, Varies (MFBNG) performed by Mayo Clinic Laboratories for (insert patient name) Patient's personal medical history is significant for Patient's family history is significant for

Due to the patient's medical history, a diagnosis of Marfan syndrome is suspected and genetic testing is recommended.

Rationale: The use of genetic testing to aid in the diagnosis of Marfan syndrome is supported by experts in the field and summarized by the 2010 revised Ghent nosology for Marfan syndrome, "In order to avoid persistent ambiguity even under the proposed criteria, molecular testing should be strongly considered because it influences the clinical management." Test results will have a direct impact on this patient's medical management, screening, and prevention of potential complications, including sudden cardiac death.

Genetic testing is used to confirm a diagnosis and/or identify at-risk individuals. This testing would allow for the unequivocal diagnosis of a gene variant causative of the patient's medical history, and would have significant implications for the patient's clinical management with regard to decision-making for ongoing imaging and surveillance, surgery, as well as medical management. For example, identification of a disease-associated *FBN1* variant would confirm the diagnosis of Marfan syndrome, and warrant ongoing echocardiographic screening to monitor the size of the aorta and prevent serious complications, such as aortic dissection. Additionally, identification of a disease-associated variant in *FBN1* would provide guidance regarding the best timing for surgical intervention on the aorta, given that different genes are known to have higher or lower risk of aortic dissection at different aortic dimensions. In summary, a positive genetic test result would provide a definitive cause for this patient's medical history and would ensure this patient is being treated appropriately.

A negative FBN1 test result could also be informative. A negative result may help to reinforce that the patient does not have Marfan syndrome or, alternatively, it could indicate that additional genetic testing for genes known to cause similar disorders (*TGFBR1*, *TGFBR2*, *SMAD3*, *TGFB2*, *ACTA2*, etc) should be considered to assess for an alternate diagnosis and allow for gene-specific management and screening.

Marfan syndrome is inherited in an autosomal dominant fashion, and each child is at a 50% risk to inherit a causative variant from an affected parent. When a familial variant has been identified, genetic testing can identify family members who are not at increased risk to develop the complications and symptoms associated with Marfan syndrome. No other test can reliably differentiate unaffected family members, who do not require further health screening, from presymptomatic affected family members, who must be followed closely by a cardiologist.

Test requested: *FBN1* Full Gene Sequencing with Deletion/Duplication, Varies (MFBNG) is a cost-effective test that utilizes next-generation sequencing (NGS) to evaluate the *FBN1* gene for Marfan syndrome-associated variants.

Laboratory information: Testing would be performed at Mayo Clinic Laboratories (TIN# 411346366 / NPI# 1093792350), a CAP-accredited and CLIA-certified laboratory, using 2020 CPT code: 81408.

Page 3 of 4 MC7226-50rev1224

Sincerely,			
Ordering Provider Name	 		

Thank you for your thoughtful consideration of our preauthorization request. We look forward to hearing back from you.

References

Contact information

- 1. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476-485. doi:10.1136/jmg.2009.072785
- 2. Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538-3700. doi:10.1093/eurheartj/ehae179
- 3. Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022;146(24):e334-e482. doi:10.1161/CIR.0000000000001106

Page 4 of 4 MC7226-50rev1224

MAYO CLINIC LABORATORIES

200 First Street SW Rochester, Minnesota 55905 800-447-6424

Patient Name (First Middle Last)	MCL Order Number

Advance Beneficiary Notice of Noncoverage (ABN)

Note: If Medicare doesn't pay for Items and Services below, you may have to pay.

Medicare does not pay for everything, even some care that you or your health care provider have good reason to think you need. We expect Medicare may not pay for the Items and Services below.

Items and Services	Reason Medicare May Not Pay	Estimated Cost
MFBNG/FBN1 Full Gene Sequencing with Deletion/ Duplication, Varies	Patient's personal and family history of cancer does not meet Medicare's medical necessity coverage criteria for this laboratory test.	\$2,350.00

WHAT YOU NEED TO DO NOW:

- Read this notice, so you can make an informed decision about your care.
- Ask us any questions that you may have after you finish reading.
- Choose an option below about whether to receive the Items and Services listed above.

Note: If you choose Option 1 or 2, we may help you to use any other insurance that you might have, but Medicare cannot require us to do this.

	meet educate as as as as
Options: Chec	ck only one box. We cannot choose a box for you.
OPTION 1.	I want the Items and Services listed above. You may ask to be paid now, but I also want Medicare billed for an official decision on payment, which is sent to me on a Medicare Summary Notice (MSN). I understand that if Medicare doesn't pay, I am responsible for payment, but I can appeal to Medicare by following the directions on the MSN. If Medicare does pay, you will refund any payments I made to you, less co-pays or deductibles.
OPTION 2.	I want the Items and Services listed above, but do not bill Medicare. You may ask to be paid now as I am responsible for payment. I cannot appeal if Medicare is not billed.
\square option 3.	I don't want the Items and Services listed above. I understand with this choice I am not responsible for payment, and I cannot appeal to see if Medicare would pay.
Additional Info	rmation:

This notice gives our opinion, not an official Medicare decision. If you have other questions on this notice or Medicare billing, call **1-800-MEDICARE** (1-800-633-4227/**TTY**: 1-877-486-2048).

Signing below means that you have received and understand this notice. You may ask to receive a copy.

Signature	Date (mm-dd-yyyy)

You have the right to get Medicare information in an accessible format, like large print, Braille, or audio. You also have the right to file a complaint if you feel you've been discriminated against. Visit Medicare.gov/about-us/accessibility-nondiscrimination-notice.

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0566. The time required to complete this information collection is estimated to average 7 minutes per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Baltimore, Maryland 21244-1850.

Form CMS-R-131 (Exp. 01/31/2026)

Form Approved OMB No. 0938-0566